Short Bowel Syndrome Market Insights, Size, Share, Growth and Report 2023-2030

Market Overview:
Short bowel syndrome (SBS) is a metabolic disorder caused by malfunctioning or removal of the small intestine due to digestive illness surgery. This can lead to malabsorption, diarrhoea, steatorrhea, fluid and electrolyte imbalances, and malnutrition.

The North American region currently dominates the global short bowel syndrome market and is expected to maintain this position throughout the forecast period. This is mainly due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved to improve intestinal absorption in patients with SBS in the U.S.

The rise of sedentary lifestyles and increased consumption of unhealthy and junk food has also contributed to the growing prevalence of intestinal disorders, further driving market growth in the region.

Market Size and Growth Rate:
The Short Bowel Syndrome Market is estimated to reach at a CAGR of 15.9% during the forecast period (2023-2030).

Download a Free PDF Sample - https://www.datamintelligence.com/download-sample/short-bowel-syndrome-market

Market Drivers: Increasing Penetration of GLP-2 Drugs for SBS Intestinal Failure (SBS-IF)
Short bowel syndrome patients may develop a rare condition known as SBS-IF, which requires a higher frequency of parenteral support for treatment. Typically, patients receive this treatment for around 5 days per week. However, long-term use of parenteral support can hinder daily activities, increase hospitalization rates, and lead to complications. As a result, GLP-2-based drugs have become more prevalent in the market to address these issues.

GLP-2 drugs for SBS-IF are more widely used in developed countries like the U.S., Germany, and France, compared to developing countries. This is because patients and healthcare providers in these countries tend to prefer GLP-2 drugs, there is higher reimbursement, and the drugs are more readily available.

Market Trends:
The problems of prolonged parenteral nutrition treatment have led to a preference for GLP-2 medicines over TPN. Total parenteral feeding risks liver and renal failure and catheter sepsis. Due to their ability to increase intestine absorption and daily dosing frequency, GLP-2 medicines are becoming more popular. Along with the expanding penetration rate of GLP-2 treatments for intestinal failure, market demand for GLP-2 pharmaceuticals is rising. This, coupled with major firms' current clinical studies on GLP-2-based pharmaceuticals, is boosting market adoption.

Market Segmentation Analysis:
The short bowel syndrome market is segmented by drug class into GLP-2, growth hormone, glutamine, others; by distribution channel into hospital pharmacies, retail pharmacies, and others.

Based on the distribution channel, the retail pharmacies segment is expected to register the highest CAGR during forecast period and generate the highest revenue among the distribution channel segment in 2022. The dominance is attributed to the growing number of retail pharmacies in countries such as the U.S., U.K., India, and others. This, along with the preferential shift of patients toward online platforms, has increased the focus of major players in collaborating with online pharmacies, further propelling the segment growth.

For more detailed information - https://www.datamintelligence.com/research-report/short-bowel-syndrome-market

Geographical Analysis:
The global short bowel syndrome market is analyzed across North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
The market in North America stood at USD 596.9 million in 2021. The presence of a large patient pool adopting advanced drugs and requiring new treatment options is fueling the short bowel syndrome market growth in this region. Also, the extended use of approved drugs to treat both adult and pediatric populations, along with the presence of a wide range of pipeline products, is anticipated to contribute to the market growth in this region during the forecast period.

Some of the key players:
1. OxThera Inc
2. VectivBio AG
3. Nutrinia
4. Merck KGaA
5. Pfizer Inc

Trending Topics
Renal Insufficiency Market - https://www.datamintelligence.com/research-report/renal-insufficiency-market
Foveal Atrophy Market - https://www.datamintelligence.com/research-report/foveal-atrophy-market
Typhoid Fever Market - https://www.datamintelligence.com/research-report/typhoid-fever-market
Color Blindness Market - https://www.datamintelligence.com/research-report/color-blindness-market
Coloboma Treatment Market - https://www.datamintelligence.com/research-report/coloboma-treatment-market
Chronic Bronchitis Treatment Market - https://www.datamintelligence.com/research-report/chronic-bronchitis-treatment-market

Contact Us:
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence:
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.